InvestorsHub Logo
Followers 262
Posts 35002
Boards Moderated 3
Alias Born 02/22/2005

Re: None

Sunday, 12/17/2023 3:13:55 PM

Sunday, December 17, 2023 3:13:55 PM

Post# of 647741
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
https://ih.advfn.com/stock-market/NASDAQ/arcutis-biotherapeutics-ARQT/stock-news/92826417/fda-approves-arcutis-zoryve-roflumilast-topical


"A fool and his money are soon parted.” ~Thomas Tusser

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.